speaker-photo

ROMUALDO BARROSO DE SOUSA (BRA)

Clinical Oncologist, Head of Research in Oncology and National Leader of Breast Cancer – DASA Oncology. Postdoc at the Dana-Farber Cancer Institute/Harvard Medical School

8:00AM FROM 6:50PM

WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER

WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER

FACE-TO-FACE 

GRUPO ONCOCLÍNICAS

Coordinators:
CRISTIANO AUGUSTO ANDRADE DE RESENDE (BRA)
LEANDRO GONÇALVES OLIVEIRA (BRA)
ROMUALDO BARROSO DE SOUSA (BRA)
VICTOR DOMINGOS LISITA ROSA (BRA)

11:00AM FROM 11:20AM

WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER

Thinking outside the box in the advanced disease: new biomarkers and immunotherapy indications

ROMUALDO BARROSO DE SOUSA (BRA)

4:30PM FROM 6:30PM

WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER

PART 4 - ADCs

Coordinator:
ROMUALDO BARROSO DE SOUSA (BRA)

5:50PM FROM 6:10PM

WORKSHOP - ADVANCES AND CHALLENGES ENCOMPASSING SYSTEMIC THERAPY IN BREAST CANCER

What’s next in terms of breast cancer treatment with ADCs

ROMUALDO BARROSO DE SOUSA (BRA)

7:50PM FROM 8:10PM

BREAST CANCER PRECEPTORY | MASTERCLASS

When can we use genomic signatures to predict the benefit of chemotherapy in patients with HR-positive, HER-2-negative luminal disease?

ROMUALDO BARROSO DE SOUSA (BRA)

8:50AM - 9:15AM

MAIN AUDITORIUM

Mini conference: The treatment future of hormone positive advanced breast cancer

Chairman:
GABRIEL FELIPE SANTIAGO (BRA)
Speaker:
ROMUALDO BARROSO DE SOUSA (BRA)

2:40PM FROM 3:00PM

CLINICAL RESEARCH WORKSHOP

Is there any difference in conducting a phase 1 trial?

ROMUALDO BARROSO DE SOUSO (BRA)

1) Which barriers must be broken?
2) What are the greatest concerns in phase 1 trials?
3) Tips: how to persuade the sponsor that your center is ready for a phase 1 trial?